84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]朱麗英,胡春艷,贠春燕,等.血清Ⅰ型前膠原氨基端前肽與Ⅰ型膠原羧基端肽β特殊序列在惡性腫瘤骨轉(zhuǎn)移診斷和病情評(píng)估及療效評(píng)價(jià)中的應(yīng)用價(jià)值[J].中醫(yī)正骨,2018,30(06):30-33.
　ZHU Liying,HU Chunyan,YUN Chunyan,et al.Applied values of serum N-terminal propeptide of typeⅠprecollagen and β cross-linked C-telopeptide of typeⅠcollagen in diagnosis,severity assessment and therapeutic efficacy evaluation of bone metastasis of malignant tumors[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(06):30-33.
點(diǎn)擊復(fù)制

血清Ⅰ型前膠原氨基端前肽與Ⅰ型膠原羧基端肽β特殊序列 在惡性腫瘤骨轉(zhuǎn)移診斷和病情評(píng)估及療效評(píng)價(jià)中的應(yīng)用價(jià)值()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第30卷
期數(shù):
2018年06期
頁碼:
30-33
欄目:
臨床研究
出版日期:
2018-06-20

文章信息/Info

Title:
Applied values of serum N-terminal propeptide of typeⅠprecollagen and β cross-linked C-telopeptide of typeⅠcollagen in diagnosis,severity assessment and therapeutic efficacy evaluation of bone metastasis of malignant tumors
作者:
朱麗英; 胡春艷; 贠春燕; 李曉利
河南科技大學(xué)第二附屬醫(yī)院,河南 洛陽 471000
Author(s):
ZHU Liying; HU Chunyan; YUN Chunyan; LI Xiaoli
The Second Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,Henan,China
關(guān)鍵詞:
腫瘤轉(zhuǎn)移;  骨腫瘤;  Ⅰ型前膠原氨基端前肽;  Ⅰ型膠原羧基端肽β特殊序列
Keywords:
neoplasm metastasis;  bone neoplasms;  N-terminal propeptide of typeⅠprecollagen;  β cross-linked C-telopeptide of typeⅠcollagen
文獻(xiàn)標(biāo)志碼:
A
摘要:
目的:探討血清Ⅰ型前膠原氨基端前肽(N-terminal propeptide of typeⅠprecollagen,PⅠNP)與Ⅰ型膠原羧基端肽β特殊序列(β cross-linked C-telopeptide of typeⅠcollagen,β-CTX)在惡性腫瘤骨轉(zhuǎn)移診斷、病情評(píng)估及療效評(píng)價(jià)中的應(yīng)用價(jià)值。方法:回顧性分析2015年3月至2017年3月收治的115例惡性腫瘤患者的臨床資料。根據(jù)腫瘤是否出現(xiàn)骨轉(zhuǎn)移分為骨轉(zhuǎn)移組和無骨轉(zhuǎn)移組,根據(jù)骨轉(zhuǎn)移數(shù)目將骨轉(zhuǎn)移組分為骨轉(zhuǎn)移數(shù)目<3個(gè)組和骨轉(zhuǎn)移數(shù)目≥3個(gè)組,根據(jù)世界衛(wèi)生組織實(shí)體瘤近期療效評(píng)價(jià)標(biāo)準(zhǔn)中的骨轉(zhuǎn)移評(píng)價(jià)標(biāo)準(zhǔn)將骨轉(zhuǎn)移組分為治療有效組和治療無效組。比較治療前骨轉(zhuǎn)移組和無骨轉(zhuǎn)移組,骨轉(zhuǎn)移數(shù)目<3個(gè)組和骨轉(zhuǎn)移數(shù)目≥3個(gè)組的血清PⅠNP和β-CTX含量,以及骨轉(zhuǎn)移組治療前后的血清PⅠNP和β-CTX含量。結(jié)果:骨轉(zhuǎn)移組48例,無骨轉(zhuǎn)移組67例,骨轉(zhuǎn)移組的血清PⅠNP和β-CTX含量均高于無骨轉(zhuǎn)移組[(110.31±15.67)ng·mL-1,(45.56±8.65)ng·mL-1,t=3.146,P=0.002;(0.58±0.02)ng·mL-1,(0.36±0.01)ng·mL-1,t=2.858,P=0.005]。骨轉(zhuǎn)移數(shù)目<3個(gè)組21例,骨轉(zhuǎn)移數(shù)目≥3個(gè)組27例,骨轉(zhuǎn)移數(shù)目<3個(gè)組的血清PⅠNP和β-CTX含量均低于骨轉(zhuǎn)移數(shù)目≥3個(gè)組[(102.41±12.34)ng·mL-1,(116.45±17.48)ng·mL-1,t=3.121,P=0.003;(0.56±0.01)ng·mL-1,(0.58±0.04)ng·mL-1,t=2.058,P=0.045]。48例骨轉(zhuǎn)移患者中,42例針對(duì)原發(fā)腫瘤進(jìn)行了化療和放療,并應(yīng)用了雙磷酸鹽藥物治療; 其余6例均采用鎮(zhèn)痛藥物進(jìn)行姑息治療。治療2個(gè)月后,治療有效34例、無效14例,治療有效組的血清PⅠNP和β-CTX含量均較治療前下降[(97.14±17.32)ng·mL-1,(105.77±15.04)ng·mL-1,t=9.890,P=0.000;(0.52±0.03)ng·mL-1,(0.57±0.02)ng·mL-1,t=11.655,P=0.000],治療無效組的血清PⅠNP和β-CTX含量與治療前相比差異均無統(tǒng)計(jì)學(xué)意義[(118.24±20.42)ng·mL-1,(121.31±16.30)ng·mL-1,t=1.815,P=0.093;(0.59±0.04)ng·mL-1,(0.60±0.03)ng·mL-1,t=0.780,P=0.450]。結(jié)論:對(duì)惡性腫瘤患者進(jìn)行血清PⅠNP和β-CTX含量測(cè)定,有助于早期發(fā)現(xiàn)骨轉(zhuǎn)移、評(píng)估骨轉(zhuǎn)移程度和評(píng)價(jià)骨轉(zhuǎn)移治療效果。
Abstract:
Objective:To explore the applied values of serum N-terminal propeptide of typeⅠprecollagen(PⅠNP)and β cross-linked C-telopeptide of typeⅠcollagen(β-CTX)in diagnosis,severity assessment and therapeutic efficacy evaluation of bone metastasis of malignant tumors.Methods:The medical records of 115 patients with malignant tumors recruited from March 2015 to March 2017 were analyzed retrospectively.The patients were divided into bone metastasis group and non-bone metastasis group according to whether bone metastases of malignant tumor were found.The patients in bone metastasis group were divided into<3 subgroup and≥3 subgroup according to the number of bone metastases and effective treatment group and ineffective treatment group according to the evaluation criteria for bone metastasis which was extracted from short-term efficacy evaluation criteria for solid tumors issued by World Health Organization(WHO).The serum contents of PⅠNP and β-CTX were compared between bone metastasis group and non-bone metastasis group and between bone metastasis number of<3 subgroup and bone metastasis number of≥3 subgroup before the treatment,moreover,the serum contents of PⅠNP and β-CTX were compared between pre-treatment and post-treatment in bone metastasis group.Results:The serum contents of PⅠNP and β-CTX were higher in bone metastasis group(48 cases)compared to non-bone metastasis group(67 cases)(110.31+/-15.67 vs 45.56+/-8.65 ng/mL,t=3.146,P=0.002; 0.58+/-0.02 vs 0.36+/-0.01 ng/mL,t=2.858,P=0.005).The serum contents of PⅠNP and β-CTX were lower in bone metastasis number of<3 subgroup(21 cases)compared to bone metastasis number of≥3 subgroup(27 cases)(102.41+/-12.34 vs 116.45+/-17.48 ng/mL,t=3.121,P=0.003; 0.56+/-0.01 vs 0.58+/-0.04 ng/mL,t=2.058,P=0.045).Forty-two out of 48 patients with bone metastases were treated with chemotherapy and radiotherapy aiming at primary tumor and were treated with bisphosphonates,while the others were treated with palliative therapy by using analgesic drugs.After 2-month treatment,34 patients got a good therapeutic result and 14 patients got a bad therapeutic result.The serum contents of PⅠNP and β-CTX decreased in effective treatment group(97.14+/-17.32 vs 105.77+/-15.04 ng/mL,t=9.890,P=0.000; 0.52+/-0.03 vs 0.57+/-0.02 ng/mL,t=11.655,P=0.000),and there was no statistical differences in the serum contents of PⅠNP and β-CTX between pre-treatment and post-treatment in ineffective treatment group(118.24+/-20.42 vs 121.31+/-16.30 ng/mL,t=1.815,P=0.093; 0.59+/-0.04 vs 0.60+/-0.03 ng/mL,t=0.780,P=0.450).Conclusion:Determining the serum contents of PⅠNP and β-CTX is helpful to early detection,severity assessment and therapeutic efficacy evaluation of bone metastasis for patients with malignant tumor.

參考文獻(xiàn)/References:

[1] 周際昌.實(shí)用腫瘤內(nèi)科學(xué)[M].2版.北京:人民衛(wèi)生出版社,2005:45-48. [2] 張萌萌.中國老年學(xué)學(xué)會(huì)骨質(zhì)疏松委員會(huì)骨代謝生化指標(biāo)臨床應(yīng)用專家共識(shí)[J].中國骨質(zhì)疏松雜志,2014,20(11):1263-1272. [3] TANK LB,KARSDAL MA,CHRISTIANSEN C,et al.Biochemical approach to the detection and monitoring of metastatic bone disease:what do we know and what questions need answers?[J].Cancer Metastasis Rev,2006,25(4):659-668. [4] 唐瓊,趙輝,賈銳,等.BAP和β-CTX與肺癌骨轉(zhuǎn)移進(jìn)展程度的相關(guān)性[J].中國肺癌雜志,2013,16(3):144-147. [5] FERREIRA A,ALHO I,CASIMIRO S,et al.Bone remodeling markers and bone metastases:From cancer research to clinical implications[J].Bonekey Rep,2015,4:668. [6] 于世英.惡性腫瘤骨轉(zhuǎn)移的診斷與治療[M].2版.北京:中國協(xié)和醫(yī)科大學(xué)出版社,2012:5. [7] 吳曉徽,陸漢魁.骨代謝指標(biāo)在腫瘤骨轉(zhuǎn)移診治中的應(yīng)用[J].腫瘤,2007,27(6):505-507. [8] HERRMANN M,SEIBEL MJ.The amino-and carboxyterminal cross-linked telopeptides of collagen type I,NTX-I and CTX-I:a comparative review[J].Clin Chim Acta,2008,393(2):57-75. [9] LUMACHI F,SANTEUFEMIA DA,DEL CONTE A,et al.Carboxy-terminal telopeptide(CTX)and amino-terminal propeptide(PINP)of type I collagen as markers of bone metastases in patients with non-small cell lung cancer[J].Anticancer Res,2013,33(6):2593-2596. [10] 彭東,劉學(xué)芬,劉徽婷,等.骨代謝指標(biāo)結(jié)合全身骨顯像在腫瘤骨轉(zhuǎn)移早期診斷中的臨床價(jià)值[J].國際檢驗(yàn)醫(yī)學(xué)雜志,2017,38(17):2395-2398. [11] 吳春嬌,馬麗霞,朱晶,等.聯(lián)合檢測(cè)乳腺癌骨轉(zhuǎn)移患者中尿Ⅰ型膠原氨基末端肽和Ⅰ型膠原羧基末端肽的臨床意義[J].中華腫瘤雜志,2016,38(9):693-697. [12] 潘興喜,楊文,楊畫,等.血清β-CTX、PINP在肺癌骨轉(zhuǎn)移診斷中的意義[J].中華臨床醫(yī)師雜志(電子版),2015,9(9):1735-1736. [13] 韓麗敏,魏麗榮,杜玉珍.骨代謝標(biāo)志物tP1NP和β-CTx及BAP在肺癌骨轉(zhuǎn)移中的臨床應(yīng)用[J].中華檢驗(yàn)醫(yī)學(xué)雜志,2017,40(11):860-864. [14] 朱禮.肺癌骨轉(zhuǎn)移血清腫瘤標(biāo)志物水平及放療對(duì)血清PINP和β-CTX水平的影響分析[J].河北醫(yī)學(xué),2017,23(3):394-398. [15] 張秋華,王靜,李靜,等.PICP和β-CTX在乳腺癌骨轉(zhuǎn)移診斷和隨訪中的價(jià)值[J].湖南師范大學(xué)學(xué)報(bào)(醫(yī)學(xué)版),2017,14(1):150-153. [16] 潘興喜,楊文,楊畫,等.肺癌骨轉(zhuǎn)移患者放療前后血清β-CTX和PINP水平變化及其與療效的關(guān)系[J].山東醫(yī)藥,2015,55(8):31-33.

相似文獻(xiàn)/References:

[1]劉玉珂,李培嶺,王娜,等.CT引導(dǎo)下多靶點(diǎn)穿刺活檢在骨腫瘤診斷中的應(yīng)用價(jià)值[J].中醫(yī)正骨,2017,29(04):46.
[2]萬春友.外固定技術(shù)在骨科領(lǐng)域的應(yīng)用[J].中醫(yī)正骨,2019,31(10):1.
[3]史炎鑫,海國棟,竇浚峰.Ilizarov骨搬移術(shù)治療下肢骨腫瘤切除術(shù)后骨缺損[J].中醫(yī)正骨,2019,31(10):63.
[4]劉艷,石麗紅,謝新立,等.18F-FDG PET/CT在未知原發(fā)灶腫瘤骨轉(zhuǎn)移診斷中的價(jià)值[J].中醫(yī)正骨,2020,32(09):39.
[5]蔡慶虎,許崇永,邱乾德.骨上皮樣血管內(nèi)皮瘤的影像學(xué)表現(xiàn)[J].中醫(yī)正骨,2020,32(11):12.
[6]杜彪,韓星敏,劉艷,等.超級(jí)骨顯像影像學(xué)特征診斷惡性腫瘤骨轉(zhuǎn)移和代謝性骨病的應(yīng)用價(jià)值[J].中醫(yī)正骨,2022,34(07):46.

更新日期/Last Update: 2018-10-30